Home » Newsletters » BioWorld Science

BioWorld Science

March 17, 2017

View Archived Issues

Fortress Biotech launches subsidiary Cyprium Therapeutics

National Institutes of Health awards SBIR phase II grant to TherapyXinc

Bellicum initiates phase I study of BPX-701 in relapsed or refractory myeloid neoplasms

Acceleron plans phase II trial of ACE-83 in Charcot-Marie-Tooth disease

Medicenna collaborates with MD Anderson on fusion protein therapeutics targeting IL4R

Aerpio Pharmaceuticals completes reverse merger

25-hydroxycholesterol protects against ZIKV-induced microcephaly in vivo

Tempus and University of Chicago establish collaboration in breast cancer

Bumetanide improves symptoms of autism; Servier and Neurochlore to collaborate on treatment

PTC Therapeutics to acquire Emflaza for the treatment of Duchenne muscular dystrophy in U.S.

Theralase demonstrates 18-month stability of its next-generation anticancer PDC, TLD-1433

Momotaro-Gene raises funding to support development of Ad-SGE-REIC

Clinigen partners with Diurnal to launch European managed access program for Infacort and Chronocort

Provecs, Medac and Cevec establish adenoviral vector collaboration in oncology

FDA issues complete response letter for ZS-9 for hyperkalemia

23-gene signature distinguishes malignant melanoma from benign nevi

New trial to combine Reolysin with Imnovid or Revlimid in patients with relapsing myeloma

Bioequivalence demonstrated for gemigliptin/rosuvastatin FDC and individual drugs

BIO-FLARE collaboration explores biological factors that trigger flares in rheumatoid arthritis

Chinese funding supports PegBio's development of GLP-1 analogue PB-119

Bristol-Myers Squibb patents activin receptor-like kinase 5 inhibitors

Arbutus licenses LNP technology to Alexion for use in rare disease program

Auckland Uniservices discloses new IDO and/or TDO inhibitors

Circassia reaches agreement with AstraZeneca on U.S. commercial rights for Tudorza and Duaklir

Incyte Corp discovers TAM kinases inhibitors

Taiho Pharmaceutical presents HER2 inhibitors

Actelion Pharmaceuticals discovers antibacterial annulated pyrrolidin-2-one derivatives

Jiangsu Hansoh Pharmaceutical Group, Shanghai Hansoh Biomedical present angiotensin AT2 antagonists

Bellus Health to sell Thallion Pharmaceuticals subsidiary to Taro

Genentech and Xenon Pharmaceuticals develop Nav1.7 channel blockers

Sunshine Lake Pharma identifies urate transporter 1/xanthine oxidase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...